OPKO Health Files 13D/A Amendment on GeneDx Holdings
Ticker: OPK · Form: SC 13D/A · Filed: Jul 5, 2024 · CIK: 944809
| Field | Detail |
|---|---|
| Company | Opko Health, INC. (OPK) |
| Form Type | SC 13D/A |
| Filed Date | Jul 5, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $26.4607, $31.20, $2,457,285 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-change, sec-filing, amendment
TL;DR
OPKO Health updated its stake in GeneDx Holdings. Watch for more details.
AI Summary
OPKO Health, Inc. filed an amendment to its Schedule 13D on July 5, 2024, regarding its beneficial ownership of GeneDx Holdings Corp. The filing indicates a change in the reporting person's holdings, though specific new dollar amounts or percentages are not detailed in this excerpt. OPKO Health, Inc. is the filer, and GeneDx Holdings Corp. is the subject company.
Why It Matters
This filing signals a potential shift in control or significant stake changes for GeneDx Holdings Corp., which could impact its stock price and strategic direction.
Risk Assessment
Risk Level: medium — Changes in beneficial ownership filings can precede significant corporate actions or market movements.
Key Players & Entities
- OPKO HEALTH, INC. (company) — Filer of the Schedule 13D/A
- GeneDx Holdings Corp. (company) — Subject company of the Schedule 13D/A
- Sema4 Holdings Corp. (company) — Former name of GeneDx Holdings Corp.
- CM Life Sciences, Inc. (company) — Former name of GeneDx Holdings Corp.
FAQ
What specific changes in beneficial ownership are reported by OPKO Health, Inc. in this 13D/A filing?
The provided excerpt states that the filing is an amendment to Schedule 13D and indicates a change in the reporting person's holdings, but does not specify the exact nature or extent of the change in beneficial ownership.
When was this Schedule 13D/A filing submitted to the SEC?
The filing was submitted on July 5, 2024.
What is the Central Index Key (CIK) for OPKO Health, Inc.?
The CIK for OPKO Health, Inc. is 0000944809.
What is the former name of GeneDx Holdings Corp. that is mentioned in the filing?
GeneDx Holdings Corp. was formerly known as Sema4 Holdings Corp. and prior to that, CM Life Sciences, Inc.
What is the business address of OPKO Health, Inc. as listed in the filing?
The business address for OPKO Health, Inc. is 4400 BISCAYNE BLVD., MIAMI, FL 33137.
Filing Stats: 1,009 words · 4 min read · ~3 pages · Grade level 9.6 · Accepted 2024-07-05 16:14:38
Key Financial Figures
- $0.0001 — suer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securiti
- $26.4607 — the open market at prices ranging from $26.4607 to $31.20 per share for an aggregate sa
- $31.20 — rket at prices ranging from $26.4607 to $31.20 per share for an aggregate sale price o
- $2,457,285 — n aggregate sale price of approximately $2,457,285. ITEM 5. Interest in Securities of t
Filing Documents
- opk20240613_sc13da.htm (SC 13D/A) — 51KB
- 0001437749-24-022249.txt ( ) — 53KB
is amended by adding the following paragraph to the end of the item
Item 4 is amended by adding the following paragraph to the end of the item: In a series of transactions between July 1, 2024 and July 3, 2024, OPKO sold a total of 89,082 shares of GeneDx Common Stock on the open market at prices ranging from $26.4607 to $31.20 per share for an aggregate sale price of approximately $2,457,285. ITEM 5. Interest in Securities of the Issuer.
is deleted in its entirety and replaced with the following text
Item 5 is deleted in its entirety and replaced with the following text: (a) The Company's beneficial ownership of GeneDx Common Stock is as set forth in the table below: Name and Title of Beneficial Owner Number of Outstanding Shares Beneficially Owned Percentage of Outstanding Common Shares (1) OPKO Health, Inc. 3,469,521 13.27% ______________ (1) Based on 26,15,866 shares of GeneDx Common Stock (as defined herein) of the Issuer (as defined herein) outstanding on April 24, 2024, as set forth in the Issuer's DEF14A filed with the SEC (as defined herein) on April 29, 2024. (b) Items 7-10, inclusive, set forth on the cover page to this Amendment are hereby incorporated by reference in this Item 5. (c) In the last 60 days prior to the filing of this Amendment No. 3, OPKO sold a total of 89,082 shares of GeneDx Common Stock on the open market at prices ranging from $26.4607 to $31.20 per share for an aggregate sale price of approximately $$2,457,285. The following table sets forth the information with regard to GeneDx Common Stock sold by OPKO on the open market in the last 60 days. Date Shares of Common Stock Aggregate Purchase Price Price Per Share 7/1/24 50,000 $ 1,331,669 $ 26.6340 7/2/24 25,000 $ 728,095 $ 29.1238 7/3/24 14,082 $ 397,491 $ 28.2269 (d) Except as described herein, no other person is known by OPKO to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of the Issuer beneficially owned by them. (e) Not applicable. CUSIP No. 81663L200 Schedule 13D PAGE 4 of 4
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. OPKO Health, Inc. Dated: July 5, 2024 By: /s/ Steven D. Rubin Name: Steven D. Rubin Title: Executive Vice President - Administration